Highlights on Novel Technologies for the Detection of Antibodies to Ro60, Ro52, and SS-B

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2013 Dec 31

PMID 24376466

Citations 12

Authors

M Infantino

C Bentow

A Seaman

M Benucci

F Atzeni

P Sarzi-Puttini

B Olivito

F Meacci

M Manfredi

M Mahler

Affiliations

Soon will be listed here.

Abstract

Objective: We aimed to compare a chemiluminescent immunoassay (CIA, QUANTA Flash) on BIO-FLASH with a multiplex flow immunoassay (MFI) on BioPlex 2200 for the detection of antibodies to Ro60, Ro52, and SS-B.

Methods: The study included 241 samples, from patients suffering from systemic autoimmune diseases (n = 108) as well as disease controls (n = 133). All samples were tested for anti-Ro52, anti-Ro60, and anti-SS-B (La) antibodies on QUANTA Flash (INOVA Diagnostics, San Diego, USA) and BioPlex 2200 (Bio-Rad Laboratories Inc., Hercules, USA). Discrepant samples were tested by two independent methods: BlueDot/ANA and QUANTRIX Microarray (both D-tek, Belgium).

Results: The overall qualitative agreements were 95.4% (95% confidence interval, CI 92.0-97.7%) for anti-Ro52, 98.8% (95% CI 96.4-99.7%) for anti-Ro60, and 91.7% (95% CI 87.5-94.9%) for anti-SS-B antibodies. There were 34 discrepant samples among all assays (20 anti-SS-B, 11 anti-Ro52, 3 anti-Ro60). 30/33 of retested samples (by D-tek dot blot) agreed with the QUANTA Flash results. Similar findings were obtained with QUANTRIX Microarray kit.

Conclusion: QUANTA Flash and BioPlex 2200 show good qualitative agreement. The clinical performances were similar for anti-Ro52 and anti-Ro60 autoantibodies while differences were observed for anti-SS-B (La) antibodies.

Citing Articles

Evaluation of a New Multiparametric Microdot Array-Based Immunoassay Panel for Systemic Autoimmune Disease Diagnosis.

Infantino M, Pavia F, Grossi V, Lari B, Benucci M, Li Gobbi F J Pers Med. 2024; 14(6).

PMID: 38929828 PMC: 11205220. DOI: 10.3390/jpm14060607.

Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease-Modifying Therapies.

Armagan B, Robinson S, Bazoberry A, Perin J, Grader-Beck T, Akpek E Arthritis Care Res (Hoboken). 2021; 74(9):1559-1565.

PMID: 33742788 PMC: 8450300. DOI: 10.1002/acr.24597.

Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab.

Teitsma X, Devenport J, Jacobs J, Petho-Schramm A, Borm M, Budde P PLoS One. 2020; 15(12):e0241189.

PMID: 33301475 PMC: 7728181. DOI: 10.1371/journal.pone.0241189.

Analytical variability in the determination of anti-double-stranded DNA antibodies: the strong need of a better definition of the old and new tests.

Infantino M, Manfredi M, Merone M, Grossi V, Benucci M, Li Gobbi F Immunol Res. 2018; 66(3):340-347.

PMID: 29623613 DOI: 10.1007/s12026-018-8992-9.

Isolated positive anti-SS-B autoantibodies are not related to clinical features of systemic autoimmune diseases: Results from a routine population survey.

Jardel S, Fabien N, Hot A, Vukusic S, Tebib J, Cottin V PLoS One. 2017; 12(9):e0185104.

PMID: 28931060 PMC: 5607193. DOI: 10.1371/journal.pone.0185104.

References

Mahler M, Fritzler M, Bluthner M . Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther. 2005; 7(1):R19-29. PMC: 1064884. DOI: 10.1186/ar1455. View

Mahler M, Silverman E, Schulte-Pelkum J, Fritzler M . Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?. Autoimmun Rev. 2010; 9(11):756-60. DOI: 10.1016/j.autrev.2010.06.005. View

Avaniss-Aghajani E, Berzon S, Sarkissian A . Clinical value of multiplexed bead-based immunoassays for detection of autoantibodies to nuclear antigens. Clin Vaccine Immunol. 2007; 14(5):505-9. PMC: 1865627. DOI: 10.1128/CVI.00034-07. View

Mahler M . Sm peptides in differentiation of autoimmune diseases. Adv Clin Chem. 2011; 54:109-28. DOI: 10.1016/b978-0-12-387025-4.00005-4. View

Chan E, Fritzler M, Wiik A, Andrade L, Reeves W, Tincani A . AutoAbSC.Org -- Autoantibody Standardization Committee in 2006. Autoimmun Rev. 2007; 6(8):577-80. DOI: 10.1016/j.autrev.2007.05.001. View

Schmitt J, Papisch W . Recombinant autoantigens. Autoimmun Rev. 2003; 1(1-2):79-88. DOI: 10.1016/s1568-9972(01)00013-1. View

Hansson-Hamlin H, Ronnelid J . Detection of antinuclear antibodies by the Inno-Lia ANA update test in canine systemic rheumatic disease. Vet Clin Pathol. 2009; 39(2):215-20. DOI: 10.1111/j.1939-165X.2009.00193.x. View

Ghillani P, Andre C, Toly C, Rouquette A, Bengoufa D, Nicaise P . Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev. 2011; 10(9):509-13. DOI: 10.1016/j.autrev.2011.03.004. View

Shovman O, Gilburd B, Barzilai O, Shinar E, Larida B, Zandman-Goddard G . Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci. 2005; 1050:380-8. DOI: 10.1196/annals.1313.120. View

10.

Mahler M, Radice A, Yang W, Bentow C, Seaman A, Bianchi L . Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta. 2012; 413(7-8):719-26. DOI: 10.1016/j.cca.2012.01.004. View

11.

De Beeck K, Vermeersch P, Verschueren P, Westhovens R, Marien G, Blockmans D . Antinuclear antibody detection by automated multiplex immunoassay in untreated patients at the time of diagnosis. Autoimmun Rev. 2012; 12(2):137-43. DOI: 10.1016/j.autrev.2012.02.013. View

12.

Hanly J, Su L, Farewell V, Fritzler M . Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. J Immunol Methods. 2010; 358(1-2):75-80. DOI: 10.1016/j.jim.2010.04.005. View

13.

Fritzler M, Behmanesh F, Fritzler M . Analysis of human sera that are polyreactive in an addressable laser bead immunoassay. Clin Immunol. 2006; 120(3):349-56. DOI: 10.1016/j.clim.2006.03.007. View

14.

Bayer P, Bauerfeind S, Bienvenu J, Fabien N, Frei P, Gilburd B . Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. J Autoimmun. 1999; 13(1):89-93. DOI: 10.1006/jaut.1999.0298. View

15.

Bossuyt X . Evaluation of two automated enzyme immunoassays for detection of antinuclear antibodies. Clin Chem Lab Med. 2001; 38(10):1033-7. DOI: 10.1515/CCLM.2000.153. View

16.

Ching K, Burbelo P, Tipton C, Wei C, Petri M, Sanz I . Two major autoantibody clusters in systemic lupus erythematosus. PLoS One. 2012; 7(2):e32001. PMC: 3283706. DOI: 10.1371/journal.pone.0032001. View

17.

Copple S, Martins T, Masterson C, Joly E, Hill H . Comparison of three multiplex immunoassays for detection of antibodies to extractable nuclear antibodies using clinically defined sera. Ann N Y Acad Sci. 2007; 1109:464-72. DOI: 10.1196/annals.1398.052. View

18.

Bentow C, Swart A, Wu J, Seaman A, Manfredi M, Infantino M . Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta. 2013; 424:141-7. DOI: 10.1016/j.cca.2013.05.011. View

19.

Robinson W, Digennaro C, Hueber W, Haab B, Kamachi M, Dean E . Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med. 2002; 8(3):295-301. DOI: 10.1038/nm0302-295. View

20.

Mahler M, Fritzler M . Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci. 2010; 1183:267-87. DOI: 10.1111/j.1749-6632.2009.05127.x. View